In this study a digital measurement technique has been proposed to quantify bone formation on histological images. Two standard parietal defects were created in 30 adult rabbits. The animals were divided into six groups. Four animals of each group were randomly chosen as experimental group in which osteopontin-coated hydroxyapatite (OPN-HA) and hydroxyapatite (HA) were inserted alternatively in created defects. To observe the spontaneous healing process of defects, one animal of each group was used as control animal and these created defects did not receive any implants. The animals were sacrificed after 1, 2, 6, 12, 18 and 30 weeks. The histological sections were magnified (×100) and scanned digitally. The newly formed bone surfaces within the healing area were indicated and quantified by means of Adobe Photoshop® 7 software. This measuring technique was found to be reliable and reproducible. The results of this study show no significant differences in bone formation between the OPN-HA and non-coated HA defects, although a significant difference in bone formation was measured at the margins of the defects treated with OPN-HA.

Keywords:
Bone metabolism, Digital imaging, Hydroxyapatite, Osteopontin
1.
Charles, P., E.F. Eriksen, L. Mosekilde, F. Melsen, F.T. Jensen (1987) Bone turnover and balance evaluated by a combined calcium balance and calcium kinetic study and dynamic histomorphometry. Metabolism 36: 1118–1124.
2.
Crichton, N.J. (1998) Statistical considerations in design and analysis; in Roe, B., Webb C. (eds): Research and Development in Clinical Nursing Practice. London, Whurr, p 209.
3.
De Bie, A.C., H. Thierens, L. Dermaut, L. De Ridder (1991) The healing of cranial defects by demineralized osseous implants: a radiographic, histological and radioisotope-uptake study in rats. J Biol Buccale 19: 211–220.
4.
Eriksen, E.F. (1986) Normal and pathological remodelling of human trabecular bone: three-dimensional reconstruction of the remodelling sequence in normals and in metabolic bone disease. Endocr Rev 7: 379–408.
5.
Goldberg, A., K.J. Warner, M.C. Li, G.K. Hunter (2001) Binding of bone sialoprotein, osteopontin and synthetic polypeptides to hydroxyapatite. Connect Tissue Res 42: 25–37.
6.
Gordjestani, M., L. Dermaut, H. Thierens (1994) Infrared laser and bone metabolism: a pilot study. Int J Oral Maxillofac Surg 23: 54–56.
7.
Gordjestani, M., L. Dermaut, L. De Ridder, H. Thierens, P. De Waele, W. De Leersnijder, F. Bosman (2005) Osteopontin and bone metabolism: a histology and scintigraphy study in rats. Int J Oral Maxillofac Surg 34: 794–799.
8.
Hollinger, J.O., J.C. Kleinschmidt (1990) The critical size defect as an experimental model to test bone repair materials. J Craniofac Surg 1: 60–68.
9.
Kelpke, S.S., D. Reiff, C.W. Prince, J.A. Thompson (2001) Acidic fibroblast growth factor signalling inhibits peroxynitrite-induced death of osteoblasts and osteoblast precursors. J Bone Miner Res 16: 1917–1925.
10.
Kon, S., M. Maeda, T. Segawa, Y. Hagiwara, Y. Horikoshi, S. Chikuma, K. Tanaka, M.M. Rashid, M. Inobe, A.F. Chambers, T. Uede (2000) Antibodies to different peptides in osteopontin reveal complexities in the various secreted forms. J Cell Biochem 77: 487–498.
11.
Miyauchi, A., J. Alvarez, E. Greenfield, A. Teti, M. Grano, S. Colussi, A. Zambonin-Zallone, F.P. Ross, S.L. Teitelbaum, D. Cheresh, K.A. Hruska (2002) Recognition of osteopontin and related peptides by an αvβ3 integrin stimulates immediate cell signals in osteoclasts. J Biol Chem 266: 20369–20374.
12.
Mohr, A., C. Heiss, I. Bergmann, C. Schrader, F.W. Roemer, J.A. Lynch, C. Muhle, H.K. Genant, M. Heller (2003) Value of micro-CT as an investigative tool for osteochondritis dissecans. Acta Radiol 44: 532–537.
13.
Parfitt, A.M., M.K. Drezner, F.H. Glorieux, J.A. Kanis, H. Malluche, P.J. Meunier (1987) Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 2: 595–610.
14.
Rawlinson, A., C. Elcock, A. Cheung, A. Al-Buhairi, S. Khanna, T.F. Walsh, R.P. Ellwood (2005) An in-vitroand in-vivo methodology study of alveolar bone measurement using extra-oral radiographic alignment apparatus, Image Pro-Plus software and a subtraction programme. J Dent 33: 781–788.
15.
Schliephake, H. (2002) Bone growth factors in maxillofacial skeletal reconstruction. Int J Oral Maxillofac Surg 3: 469–484.
16.
Senger, D.R., C.A. Perruzzi, A. Papadopoulos, D.G. Tenen (1989a) Purification of a human milk protein closely similar to tumor-secreted phosphoproteins and osteopontin. Biochim Biophys Acta 966: 43–48.
17.
Senger, D.R., C.A. Perruzzi, A. Papadopoulos (1989b) Elevated expression of secreted phosphoprotein I (osteopontin, 2ar) as a consequence of neoplastic transformation. Anticancer Res 9: 1291–1300.
18.
Shinkai, R.S.A., S. de Andrade Canabarro, C.B. Schmidt, E.A. Sartori (2004) Reliability of a digital image method for measuring medial mandibular flexure in dentate subjects. J Appl Oral Sci 12: 4.
19.
Spector, J.A., J.A. Greenwald, S.M. Warren, P.J. Bouletreau, F.E. Crisera, B.J. Mehrara, M.T. Longaker (2002) Co-culture of osteoblasts with immature dural cells causes an increased rate and degree of osteoblast differentiation. Plast Reconstr Surg 109: 631–642.
20.
Vesterby, A. (1990) Star volume of marrow space and trabeculae in iliac crest: sampling procedure and correlation to star volume of first lumbar vertebra. J Bone 11: 149–155.
© 2007 S. Karger AG, Basel
2007
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.